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Nail varnish (enamel, lacquer) is an integral part of today=s beauty treatments.  It protects nail 
plates,  but  more importantly, it  enhances their  beauty, imparting colour and lustre.   It  is 
available in a myriad range of colours, it may be pearlised, some claim to be superdurable and 
chip-resistant, others claim to be fast-drying.  The basic nail varnish consists of solvents, film 
forming polymer, resins which enable the film to adhere to the nail plate and which convey 
luster  to  the  film,  plasticisers  which give flexibility and durability to  the film,  colouring 
agents and suspending agents.  Guanine crystals from fish scales and nacreous pigments may 
be included to give a pearlised effect; fibres e.g. silk, nylon, may also be included  to increase 
durability.
Borrowing from the cosmetic industry....
Incorporating drugs in nail varnish is an obvious step in the treatment of nail diseases, such as 
onychomycosis (fungal infections of the nail) and nail psoriasis, which are responsible for the 
bulk of nail disorders.  These two conditions are difficult to cure, need a long duration of 
treatment and relapse is common.  Side effects of oral anti-fungals include liver toxicity while 
treatment for nail psoriasis include monthly injection of corticosteroids into the nail  folds 
(skin around the nail plate).   Topical therapy, using nail varnish as a delivery vehicle, targets 
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the drug to its site of action; thus, drug interactions and adverse events arising from systemic 
drug  exposure  can  be  avoided.   The technology to  manufacture,  package  and apply nail 
varnish has existed for a long time, most people are familiar with nail varnish, application is 
easy and pain-free.  Upon application of the lacquer onto the nail plate (the most visible part 
of the nail), the solvent evaporates, leaving a water-insoluble polymer film on the nail plate. 
The film acts as a drug depot from which drug can be released and penetrates into the nail for 
a desired duration, e.g. a week.  The film can then be removed using cosmetic nail polish 
remover  and fresh  lacquer  can  be  applied  to  renew the  drug depot.   Like  cosmetic  nail 
varnish, drug-containing nail lacquers must be stable, have the correct viscosity for ease of 
application; once applied, the lacquer must dry quickly (in 3-5 minutes) and form an even 
film which adheres well  to nail  plates and does not come off during daily activities,  but, 
which can be removed cleanly with enamel remover and is well-tolerated locally.  In addition, 
drug-containing lacquers must be colourless and non-glossy to be acceptable to male patients. 
Most importantly, the drug must be released from the film so that it can penetrate into the nail 
and achieve fungicidal concentrations.  The current drug-containing nail varnish formulations 
are pretty similar in composition to the cosmetic ones, except for the presence of the drug, the 
absence of colourants, nacreous pigments and suspending agents and the choice of the film-
forming polymer; nitrocellulose (the main film-former in cosmetic nail varnish) is not used, 
presumably because of its explosive hazard. 
Commercially available drug-containing nail varnish
The first drug-containing nail varnish seems to be one that was used to treat nail mycoses, 
where   the  drug  was  the  anti-mycotic,  sulbentine  and  the  film-forming  polymer  was 
nitrocellulose.  This nail varnish was not universally accepted however, due to the fact that 
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only mild nail mycoses could be treated, possibly as a result of poor drug bioavailability in 
the nail plate1.  Recent advances have resulted in more effective products, namely Loceryl7 
and Penlac7, both of which are indicated for mild to moderate onychomycosis.  Loceryl7 - first 
marketed in 1992 - is a clear, colourless liquid and comprises the antifungal amorolfine (5%), 
Eudragit RL 100, glycerol triacetate, butyl acetate, ethyl acetate and ethanol.  The lacquer is 
applied 1-2 times weekly to infected nail plates for up to 6 months for fingernails or 9-12 
months for toenails.  Penlac7 was  approved by the FDA in 1999.  A clear, colourless liquid, it 
is  composed  of  the  antifungal  agent  ciclopirox  (8%),  ethyl  acetate,  isopropanol  and 
butylmonoester of poly(methylvinyl ether/maleic acid).  Penlac7 is applied once daily, for up 
to 48 weeks. The film is  removed every 7 days with alcohol before re-application of the 
lacquer.  
Following  application  of  Loceryl7 and  Penlac7 (which  contain  5%  amorolfine  and  8% 
ciclopirox respectively) to the nail plate, the solvents evaporate and a polymer film with a 
higher drug concentration (approximately 25% amorolfine or 35% ciclopirox) is left on the 
nail plate2-3.  This creates a high diffusion gradient for drug permeation into the nail plate. 
Formation of a film on the nail  plate also reduces water loss from the nail surface to the 
atmosphere; this results in hyperhydration of the upper nail plate layers4, which can also assist 
drug diffusion2.  Following application of the lacquers, amorolfine and ciclopirox were found 
to reach fungicidal concentrations in the nail plate3,5 and were found to be effective at treating 
the disease6.  The nail lacquers are also well-tolerated; adverse effects are rare and usually 
comprise mild irritation localised to the application site7-8.  Although Loceryl7 and Penlac7 are 
not usually used on their own for severe onychomycosis, there is a large body of literature 
showing  the  benefits  of  combining  the  nail  lacquers  with  conventional  oral  anti-fungal 
3
therapy in severe disease states.  These include a more effective treatment of the disease9, a 
reduction in oral drug intake and reduced cost of treatment10.  The nail lacquers could also be 
used to treat severe disease in special populations where oral therapy is contra-indicated, for 
example  in  children11,  in  pregnant  and  in  breastfeeding  women,  in  patients  with  hepatic 
and/or renal impairment and in those who perceive nail infection to be too trivial for systemic 
therapy.
Factors which influence drug permeation into the nail and thereby, success of therapy
The drug must be released from the lacquer film and penetrate into the nail plate before it can 
act.  Drug permeation into the nail  plate is normally very low as the nail  plate is a good 
barrier; in an investigation in healthy volunteers, Van Hoogdalem et al calculated that less 
than 0.2% of applied dose was taken up into nail plates after 6 weeks of application12.  The 
nail plate is a dense structure (figure 1a) that is made up of approximately 25 layers of dead, 
keratinised, flattened cells which are tightly bound to one another.  The cells at the dorsal 
surface overlap (figure 1b), giving a smooth and poorly-permeable surface. Since the nail 
plate=s permeability is so low, a drug candidate must be effective at low concentrations i.e. 
have a very high potency. A small molecular size also helps; drug flux through the nail plate 
was found to be inversely proportional to molecular size13.  There are conflicting reports on 
the influence of drug hydrophilicity/hydrophobicity on its permeation14-15.
As expected, increasing the drug concentration in the lacquer increases drug flux in the nail5 
(figure 2). This is reflected in the increased cure rate from 12% to 38% when amorolfine 
concentration  in  the  lacquer  was  increased  from 2  to  5% in  a  double-blind,  randomised 
study16.   Increasing the duration of contact  also increases flux (figure 2).   This  was also 
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reflected in a double-blind placebo-controlled studies,  where the therapeutic response was 
found to be directly related to the duration of treatment of nail psoriasis17.  Increasing the 
frequency  of  lacquer  application,  from  once  to  twice  weekly,  also  resulted  in  slightly 
increased (76.1 vs 70.6%), but not statistically significant, mycological cure rate7.  
The nature of the drug formulation is expected to influence drug partitioning from the vehicle 
into the nail plate.  There are many conflicting reports, however, about the influence of the 
vehicle, for example, regarding the presence of water, the presence of an organic co-solvent 
such as dimethyl sulfoxide, the pH of formulation, and the nature of the solvent in the nail 
lacquer on drug flux into the nail18-21.  For example, Franz (1992) reported an increased drug 
flux through and into the nail plate from a methylene chloride lacquer compared to an ethanol 
lacquer21.   The author did  not  speculate  on  the  reasons  for  the different  permeation  and 
uptake; they could include effects of the solvent on the film that was formed after solvent 
evaporation, the affinity of drug for the lacquer formulation and the effect of solvent on the 
nail plate.  Interestingly, Polak (1993) showed totally opposite effects of the two solvents; 
amorolfine concentration in human nail layers were higher following a 24-hour contact with 
ethanol lacquer compared to contact with a methylene chloride lacquer22. 
The future
The future for manufacturers of drug-containing lacquers, especially of anti-fungal containing 
lacquers is bright, given the increasing prevalence of onychomycosis, and a large number of 
patents covering anti-fungal nail lacquers have been filed. A review of the patent literature 
reveals that future pharmaceutical lacquer formulations could include, among others,:
$ ungual  permeation  enhancers,  such  as,  oxacyclohexadecan-2-one,  which  could 
increase drug flux into the nail (e.g. US 2003049307, US 2003232070, US 6224887)
5
$ keratolytic  agents such as urea,  salicylic acid, enzymes, which could also increase 
drug flux into the nail (e.g. US 5264206, US 5346692),
$ acidified  formulations  (acidification  was  found  to  enhance  drug  uptake  into  nail, 
probably via increased drug solubilisation in the nail lacquer (WO 9949835), 
$ drug combinations e.g. anti-mycotic and a steroidal anti-inflammatory agent (it has 
been suggested that the overall effectiveness of antimycotic agents may be improved 
by combining  an anti-fungal with a steroidal anti-inflammatory agent (US 6224887), 
$ vitamins which are thought to possess therapeutic activities against keratinic/psoriatic 
disorders (WO 9614048)
$ colourants,  included  to  hide  unsightly  manifestations  of  nail  disorders  (US 
2003232070), 
$ water-based  nail  lacquers,  which  would  be  environmentally-friendly  and  whose 
manufacture would be cheaper and safer, given the avoidance of flammable organic 
solvents. 
Conclusions
The permeation of topically applied drugs into the nail is low due to the poor permeability of 
the nail plate.  This has limited the success of topical therapy of nail diseases.  Also, the field 
of  ungual  drug  delivery is  young and  work  needs  to  be  done  to  resolve  the  conflicting 
reports23.  Nevertheless, the very large number of papers on the commercially available nail 
lacquers, expounding the latter=s virtues, indicates great enthusiasm for the lacquers and for 
the topical therapy of onychomycosis.  In contrast, research into lacquers for nail psoriasis 
seems to be scant.  I am sure there is untapped potential and a market out there.
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Figure 1a: nail cross-section
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Figure 1b: dorsal nail surface
9
010
20
30
40
0 1 2 3 4 5 6
drug concentration in lacquer (%)
m
cg
/c
m
2
6h
6d
Figure 2
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